Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ABBV: ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook AbbVie raises FY24 revenue view to ~$56B from ~$55.5B, consensus $55.73B AbbVie sees Q4 adjusted EPS $2.94-$2.98, consensus $2.95 AbbVie sees FY24 adjusted gross margin 84% AbbVie says ‘pleased’ with progress advancing product pipeline Disclaimer & DisclosureReport an Issue
